CSL Ltd shares rally ahead of FY26 financial results

CSL Ltd shares have seen a 12% increase this month following a significant period of decline, with investors looking toward the upcoming FY26 results for signs of a sustained turnaround. While management previously projected a net profit after tax and amortisation of approximately US$3.1 billion, specific segment performance remains a key focus.

CSL Behring faces challenges including a projected US$300 million revenue reduction due to decreased US channel inventory and a US$200 million reduction from lower albumin prices in China. Additionally, CSL Vifor faces potential regulatory hurdles in the European Union regarding Tavneos' marketing authorisation and expected impairments through FY27.

Strategic shifts are also underway, including the planned demerger of the Seqirus influenza vaccine business by the end of FY26 and an ongoing search for a permanent chief executive.